Novartis AG (NVS) stock

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30

$160.32−2.94 (-1.80%)

Close on Nov 11, 2026Market cap $305.92BP/E 22.4Yield –

Novartis ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Novartis has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?